Filing Flows › Lifecore Biomedical (LFCR) › Q3 FY25
Lifecore Biomedical (LFCR) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Apr 3, 2025
Lifecore Biomedical (LFCR) reported revenue of $35.2M for the third quarter fiscal 2025 (Q3 FY25), -2% from a year earlier and +8% from the quarter before. Operating margin was -25.7%, net loss $14.8M (42.0% of revenue).
Lifecore Biomedical, Q3 FY25: revenue $35.2M (-2% year over year), operating margin -25.7%, net loss $14.8M, operating cash flow $1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.2M | +8% | -2% |
| Operating profit | −$9.0M | — | — |
| Net earnings | −$14.8M | — | — |
| Operating cash flow | $1.2M | — | — |
What changed
Revenue was $35.2M in Q3 FY25, down 2% year over year and up 8% from the previous quarter. CDMO was the largest line at 59% of revenue. CDMO lost $1.5M year over year (down 7%), 276% of the total change.
Gross margin was 28.0%, down 5.3 points from a year earlier. Operating costs exceeded revenue by $9.0M, an operating margin of -25.7%. Operating expenses grew 48% against a revenue fall of 2%. The fastest-growing cost line was Other operating costs (+789%). The quarter ended with a net loss of $14.8M, wider than the previous quarter's $6.6M loss.
Operating cash flow was $1.2M. Non-cash charges added back $2.1M of depreciation and $2.6M of share-based compensation. Working capital and other items added $11.3M. Capital expenditures of $5.5M exceeded it, leaving free cash flow of −$4.3M.
Questions
What was Lifecore Biomedical's revenue in the third quarter fiscal 2025?
Lifecore Biomedical (LFCR) reported revenue of $35.2M for the third quarter fiscal 2025 (Q3 FY25), -2% from a year earlier and +8% from the quarter before.
Was Lifecore Biomedical profitable in the third quarter fiscal 2025?
Operating loss was $9.0M (-25.7% of revenue) and net loss $14.8M.